Abstract:Eczema or atopic dermatitis (AD) is a common problem seen in the general paediatric and dermatology clinic. It can be a major problem for the child causing itchiness with resultant scratching and thus soreness, bleeding infection and lichenification. It can adversely affect the quality of life (QoL), academic performance, and social relationships of the child as well as the QoL of their family. The 'once a day oral treatment' is an ideal option to compliment the daily battle of the topical creams and dressings, that can be a challenge for families and their child with eczema. Janus kinase (JAK) 1–selective inhibitors modulate the function of the crucial cytokines that are involved in the pathogenesis of AD. Eichenfield LF et al [JAMA Dermatol 2021; doi:10.1001/jamadermatol.2021.2830] have looked at the short-term efficacy and safety of an oral (JAK) 1–selective inhibitor called abrocitinib, in young adults who have moderate-to-severe AD. This is...

Oral once a day treatment for eczema